Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 11/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinburnine SCHEMBL689181 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL14029339 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29771389 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL456385 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29388881 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29391038 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL1897015 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL1897014 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL10509950 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL636902 | 0.89 | CYP3A4 (0.78) | CYP3A4CYP2D6LMNANR1I2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170166632-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | claimed |
| CN-106172483-A | A kind of compositions preventing and treating eating-core bean worm and preparation method thereof | 项正威 | 2016-12-07 | — | — | CN | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| WO-2007054975-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR AND OTHER ASSOCIATED DISORDERS | PANACEA BIOTEC LTD (IN) | 2007-05-18 | — | — | WO | claimed |
| US-20060183684-A1 | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent | REGENERON PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| WO-2005051365-A1 | COMPOSITION AND DEVICE FOR FACILITATING VENIPUNCTURE | MEDIS S.R.L. (IT) | 2005-06-09 | — | — | WO | claimed |
| EP-0680761-B1 | Topical medicament having cicatrizing activity | INDENA SPA (IT) | 2001-12-19 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5795575-A | Topical medicament which increases the number of capillaries in damaged skin | INDENA S.P.A. (IT) | 1998-08-18 | — | — | US | claimed |
| EP-0680761-A1 | Topical medicament having cicatrizing activity | INDENA S.p.A. (IT) | 1995-11-08 | — | — | EP | claimed |
| EP-0001021-B1 | DERIVATIVES OF PENTACYCLIC ALCALOIDS, METHOD FOR THEIR PREPARATION, APPLICATION IN THE SYNTHESIS OF PRODUCTS OF THE EBURNAMONINE GROUP AND PHARMACEUTICAL COMPOSITIONS | ROUSSEL-UCLAF (FR) | 1981-09-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | CYP3A4 1150/4885CYP2D6 1018/4885LMNA 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.